Methylation pattern analysis in prostate cancer tissue: identification of biomarkers using an MS-MLPA approach

Gurioli, Giorgia; Salvi, Samanta; Martignano, Filippo; Foca, Flavia; Gunelli, Roberta; Costantini, Matteo; Cicchetti, Giacomo; Giorgi, Ugo De; Sbarba, Persio Dello; Calistri, Daniele; Casadio, Valentina

doi:10.1186/s12967-016-1014-6

Cited by 18 publications

(12 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Park et al [24] concluded that the CpG island methylation of the SCGB3A1 gene is an early event that predominantly occurs during the preinvasive stage of breast cancer and accumulates with breast cancer progression. Moreover, Gurioli et al [25] reported that the SCGB3A1 methylation levels gradually increased from low and intermediate in healthy noncancerous tissue to high in cancerous tissue. Another study demonstrated that a three-gene panel including the SCGB3A1 gene could distinguish between breast ductal carcinoma in situ and normal breast tissues with 96% sensitivity and 87% specificity [26].…”

Section: Discussionmentioning

confidence: 99%

SCGB3A1 gene DNA methylation status is associated with breast cancer in Egyptian female patients

Nomair

Ahmed

Mohammed

et al. 2021

Egypt J Med Hum Genet

View full text Add to dashboard Cite

Background In recent years, hypermethylation of gene promoters has emerged as one of the fundamental mechanisms for the inactivation of tumor suppressor genes and has a potential role in the early detection of breast cancer. The present study is a case-control study aimed to quantify the methylation levels in the promoters of secretoglobin 3A1 (SCGB3A1), and ataxia-telangiectasia mutated (ATM) genes and evaluate their relation to clinicopathological features of the tumor in a cohort of Egyptian female patients with breast cancer. Methods Genomic deoxyribonucleic acid (DNA) was extracted from 100 tissue samples, 50 breast cancer tissues and 50 adjacent non-cancerous breast tissues, then, it was subjected to bisulfite conversion. The converted DNA was amplified by real-time PCR; then, pyrosequencing was performed to quantify DNA methylation levels in four CpG sites in ATM and SCGB3A1 gene promoters. The methylation data were presented as the percentage of average methylation of all the observed CpG sites and were calculated for each sample and each gene. Results The percentage of DNA methylation of the SCGB3A1 promoter was significantly higher in the tumor group than in the normal group (P= 0.001). However, a non-statistical significance difference was found in the DNA methylation percentage of the ATM promoter in the tumor group compared to the normal group (P = 0.315). The SCGB3A1 promoter methylation frequency was significantly associated with estrogen receptors (ER) and progesterone receptors (PR) positive tumors, lymph node metastasis, and lymphovascular invasion. However, no association was found between ATM methylation status and the different clinicopathological features of the tumor. Conclusions The findings of this work showed that the SCGB3A1 promoter methylation was significantly higher in the tumor group and was significantly associated with different clinicopathologic features in breast cancer. It may be considered as a suitable biomarker for diagnosis and prognosis. However, the promoter methylation levels of the ATM gene in breast cancer cases were unable to distinguish between breast cancer tissues and adjacent normal tissues, and there is no evidence that epigenetic silencing by ATM methylation has a role in breast cancer pathogenesis.

show abstract

Section: Discussionmentioning

confidence: 99%

SCGB3A1 gene DNA methylation status is associated with breast cancer in Egyptian female patients

Nomair

Ahmed

Mohammed

et al. 2021

Egypt J Med Hum Genet

View full text Add to dashboard Cite

show abstract

“…Twenty studies were published between 2002 and 2018 and included 1640 prostate cancer patients and 769 controls. Eight studies were conducted in Europe, [19][20][21][22][23][24][25][26] six studies were conducted in Asia, [27][28][29][30][31][32] and six studies were conducted in North America. [33][34][35][36][37][38] The quality assessment results of the included studies showed that the included studies had high quality and could be used for meta-analysis.…”

Section: Study Characteristicsmentioning

confidence: 99%

The diagnostic value of RASSF1A promoter methylation in prostate cancer: A systematic review and meta-analysis

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundRASSF1A promoter methylation is consistent with clinicopathological data and has good accuracy in distinguishing tumors. However, the diagnostic parameters vary among previous studies. A systematic review was conducted to explore the diagnostic value of RASSF1A promoter methylation in prostate cancer.MethodsA comprehensive search of the literature in the PubMed, Medline, Cochrane Library, Embase and ISI Web of Science databases up to May 21, 2020 was performed. STATA software version 12.0 and Meta-disc version 1.4 were used to analyze the data.ResultsThe pooled sensitivity was 0.64 (95% CI 0.61–0.66), the pooled specificity was 0.80 (95% CI 0.77–0.83), the PLR was 3.82 (95% CI 1.96–7.44), and the NLR was 0.29 (95% CI 0.16–0.52). Furthermore, the pooled DOR of RASSF1A promoter methylation for prostate cancer was 13.08 (95% CI: 6.56–26.08). The area under the summary ROC curve was 0.87 (95% CI: 0.84–0.90). The results of the meta-regression suggested that heterogeneity was mainly derived from publication year. Fagan’s nomogram showed that the predictive accuracy was increased significantly by detecting RASSF1A promoter methylation for diagnosing prostate cancer.ConclusionThis meta-analysis suggests that detection of the RASSF1A promoter methylation status can be used for the diagnosis of PCa. In the future, further analyses and studies of larger sample sizes in large centers are needed to confirm our conclusion.

show abstract

“…CpG methylation of the 5’ region of the RAR β gene contributes to gene silencing, and this methylation is associated with increased grades of SIL and invasive cervical cancer. Many studies have revealed that methylation of CpG islands in the promoter region of the RAR β gene induces repression of RAR β expression in several epithelial carcinomas, including cervical cancer[ 53 - 55 ].…”

Section: Epigenetic Mechanisms and Risk Of Cancer Developmentmentioning

confidence: 99%

Retinoic acid receptor beta promoter methylation and risk of cervical cancer

Wongwarangkana

Wanlapakorn

Chansaenroj

et al. 2018

WJV

View full text Add to dashboard Cite

Cervical cancer is one of the leading causes of death in women worldwide, particularly in developing countries. Human papillomavirus has been reported as one of the key etiologic factors in cervical carcinoma. Likewise, epigenetic aberrations have ability to regulate cancer pathogenesis and progression. Recent research suggested that methylation has been detected already at precancerous stages, which methylation markers may have significant value in cervical cancer screening. The retinoic acid receptor beta (RARβ) gene, a potential tumor suppressor gene, is usually expressed in normal epithelial tissue. Methylation of CpG islands in the promoter region of the RARβ gene has been found to be associated with the development of cervical cancer. To investigate whether RARβ methylation is a potential biomarker that predicts the progression of invasive cancer, we reviewed 14 previously published articles related to RARβ methylation. The majority of them demonstrated that the frequency of RARβ promoter methylation was significantly correlated with the severity of cervical epithelium abnormalities. However, methylation of a single gene may not represent the best approach for predicting disease prognosis. Analyzing combinations of aberrant methylation of multiple genes may increase the sensitivity, and thus this approach may serve as a better tool for predicting disease prognosis.

show abstract

Methylation pattern analysis in prostate cancer tissue: identification of biomarkers using an MS-MLPA approach

Cited by 18 publications

References 40 publications

SCGB3A1 gene DNA methylation status is associated with breast cancer in Egyptian female patients

SCGB3A1 gene DNA methylation status is associated with breast cancer in Egyptian female patients

The diagnostic value of RASSF1A promoter methylation in prostate cancer: A systematic review and meta-analysis

Retinoic acid receptor beta promoter methylation and risk of cervical cancer

Contact Info

Product

Resources

About